Monitoring safety and effectiveness of Tafamidis in transthyretin amyloidosis in Italy: a 3-year longitudinal multicenter study in a non-endemic area
© Cortese et al. 2015
Published: 2 November 2015
Tafamidis is a transthyretin (TTR) stabilizer able to prevent mutated TTR tetramer dissociation into amyloidogenic monomers. There have been a few encouraging studies on safety and long-term efficacy of Tafamidis in early-onset Val30Met TTR-familial amyloid polyneuropathy (TTR-FAP) patients. However, less is known about its efficacy in later stages of the disease and in non-Val30Met mutations.
Multi-center observational study on symptomatic TTR-FAP patients prescribed to receive tafamidis. We followed up patients according to a standardized protocol including general medical, cardiological and neurological assessments at baseline and every 6 months up to 3 years.
61 (42 males) patients were recruited. Only 28% of enrolled subjects had the common Val30Met mutation, mean age of onset was remarkably late (59 years) and 18% was in an advanced disease stage at study entry. Tafamidis proved safe and well-tolerated. One third of patients did not show significant progression along 36 months, independently from mutation type and disease stage. Neurological function worsened particularly in the first 6 months but slowed significantly thereafter. Fifteen percent of patients showed cardiac disease progression and 30% new onset of cardiomyopathy. A higher mBMI at baseline was associated with better preservation on neurological function.
Neuropathy and cardiomyopathy progressed in a significant proportion of patients despite treatment. However, the worsening of neurological function slowed after the first 6 months and also subjects with more advanced neuropathy, as well as patients with non-Val30Met mutation, benefited from Tafamidis treatment. Body weight preservation is an important favorable prognostic factor.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.